These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 19004076)

  • 1. The JAK2 V617F mutation and thrombosis.
    Austin SK; Lambert JR
    Br J Haematol; 2008 Nov; 143(3):307-20. PubMed ID: 19004076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.
    Colaizzo D; Amitrano L; Tiscia GL; Scenna G; Grandone E; Guardascione MA; Brancaccio V; Margaglione M
    J Thromb Haemost; 2007 Jan; 5(1):55-61. PubMed ID: 17059429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.
    Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK
    Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
    Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
    Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
    Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
    Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2V617F mutation in patients with thrombosis: to screen or not to screen?
    Xavier SG; Gadelha T; Rezende SM; Zalcberg IR; Spector N
    Int J Lab Hematol; 2011 Apr; 33(2):117-24. PubMed ID: 21118380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
    Lamy M; Palazzo P; Agius P; Chomel JC; Ciron J; Berthomet A; Cantagrel P; Prigent J; Ingrand P; Puyade M; Neau JP
    Cerebrovasc Dis; 2017; 44(3-4):97-104. PubMed ID: 28609766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.
    De Stefano V; Fiorini A; Rossi E; Za T; Farina G; Chiusolo P; Sica S; Leone G
    J Thromb Haemost; 2007 Apr; 5(4):708-14. PubMed ID: 17263783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.
    Ar MC; Hatemi G; Ekizoğlu S; Bilgen H; Saçli S; Buyru AN; Soysal T; Ülkü B; Yazici H
    Clin Appl Thromb Hemost; 2012 Jul; 18(4):421-6. PubMed ID: 22203033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
    Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
    Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis.
    Foucar CE; Stein BL
    JAMA; 2017 Jun; 317(21):2228-2229. PubMed ID: 28586872
    [No Abstract]   [Full Text] [Related]  

  • 12. Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.
    Levraut M; Legros L; Drappier C; Béné MC; Queyrel V; Raynaud S; Martis N
    J Thromb Thrombolysis; 2020 Nov; 50(4):995-1003. PubMed ID: 32266587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The JAK2 V617F mutation in patients with cerebral venous thrombosis.
    Passamonti SM; Biguzzi E; Cazzola M; Franchi F; Gianniello F; Bucciarelli P; Pietra D; Mannucci PM; Martinelli I
    J Thromb Haemost; 2012 Jun; 10(6):998-1003. PubMed ID: 22469236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2 V617F mutation associated with cerebral venous thrombosis: a report of five cases.
    Godeneche G; Gaillard N; Roy L; Mania A; Tondeur S; Chomel JC; Lavabre T; Arquizan C; Neau JP
    Cerebrovasc Dis; 2010 Jan; 29(2):206-9. PubMed ID: 20029191
    [No Abstract]   [Full Text] [Related]  

  • 15. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
    Hexner EO
    Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.
    Waiswa M; Seremba E; Ocama P; Ddungu H; Opio K; Okello C; O'shea T; Verhovsek M; Mutyabule R
    Afr Health Sci; 2014 Dec; 14(4):1069-73. PubMed ID: 25834519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?
    Zerjavic K; Zagradisnik B; Stangler Herodez S; Lokar L; Glaser Krasevac M; Kokalj Vokac N
    Acta Haematol; 2010; 124(1):49-56. PubMed ID: 20616539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CALR exon 9 mutations in idiopathic splanchnic vein thrombosis in an Australian cohort.
    Ho WK; Hong FS
    Thromb Res; 2017 Feb; 150():51-52. PubMed ID: 28024182
    [No Abstract]   [Full Text] [Related]  

  • 19. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 mutations across a spectrum of venous thrombosis cases.
    Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K
    Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.